EGFR and non-small cell lung carcinoma: Therefore, this study aimed to explore the maximum tolerated dose (MTD), activity, and safety of anlotinib combined with platinum plus pemetrexed in patients with T790M‐negative EGFR‐mutant advanced nonsquamous NSCLC (non‐sqNSCLC) after acquiring resistance to first‐ or second‐generation EGFR TKIs.